Target intelligence / Profile preview

Forkhead box protein K2 (FOXK2)

Target
FOXK2
Molecular classification
Transcription factor
01

Overview

Forkhead box protein K2 (FOXK2) is a transcription factor belonging to the forkhead family, characterized by a conserved forkhead (FKH) DNA-binding domain. FOXK2 regulates gene expression by binding specific DNA motifs, recruits chromatin-modifying complexes, and acts as a scaffold for co-regulators. It controls diverse processes such as cell proliferation, cell cycle progression, DNA repair, and embryonic development. Altered FOXK2 function or expression has been implicated in various cancers, where it can act as both a tumor suppressor and promoter, depending on context. It interacts with partners including AP-1, BAP1, ERα, and DVL, influencing signaling pathways like Wnt and estrogen receptor signaling. There are currently no direct drugs available for FOXK2, but its broad involvement in oncogenesis and cell fate regulation makes it a significant molecular target of interest for future therapeutic development[1][2][3].

Other names
Forkhead box K2Interleukin enhancer-binding factor 1ILFILF-1ILF1nGTBPG/T-mismatch specific binding proteinFOXK1 (note: FOXK1 is a closely related family member, sometimes confused as an alias)cellular transcription factor ILF-1
02

Mechanism of action

Not applicable (no direct drugs known). Research is ongoing for indirect or pathway-based modulation.

03

Biological functions

Regulation of transcriptionChromatin binding and remodelingCell cycle progressionDNA damage response/repairEmbryonic developmentRegulation of cell proliferationApoptosisMetabolism
04

Disease associations

Cancer (including breast, colorectal, lung, and other cancers)Potential links to other proliferative or developmental disorders (evidence primarily exists for tumorigenic roles)
05

Safety considerations

Lack of selective inhibitors hampers pharmacological studiesBroad physiological role raises risk of off-target effects if targetedPotential for disrupting normal cell cycle and tissue regeneration[1][2]
06

Interacting drugs

None currently identified or in clinical use for direct targeting of FOXK2[1]
07

Biomarkers

Elevated expression or functional modification in cancer tissues, especially breast and colorectal cancerPotential prognostic and diagnostic involvement under investigation[1][2]

Beyond the preview

Go deeper on Forkhead box protein K2 (FOXK2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forkhead box protein K2 (FOXK2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call